Article Details
Retrieved on: 2018-03-02 04:59:59
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Roche's purchase of <b>Flatiron Health</b> will accelerate the development of real-world data suitable for supporting regulatory decisions, said Daniel O'Day, CEO of Roche Pharmaceuticals. “They have very good coverage of cancer lives in the United States, but it's roughly 30 percent, so they have the scale ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here